S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
Log in
NASDAQ:CORI

Corium International Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$12.68
0.00 (0.00 %)
(As of 11/27/2018)
Add
Compare
Today's Range
$12.68
Now: $12.68
$12.68
50-Day Range N/A
52-Week Range
$7.17
Now: $12.68
$13.93
VolumeN/A
Average Volume577,723 shs
Market Capitalization$459.65 million
P/E RatioN/A
Dividend YieldN/A
Beta0.87
Corium International, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; and Crest Whitestrips for teeth whitening. The company's products under pipeline comprise Twirla, a combination hormonal contraceptive patch, which has completed Phase III clinical trials to deliver ethinyl estradiol and levonorgestrel hormones; MicroCor hPTH(1-34), a transdermal system that has completed Phase 1 and Phase II a clinical trials for the treatment of severe osteoporosis; and Donepezil and Memantine transdermal systems, which completed Phase I clinical trials for the treatment of Alzheimer's disease. In addition, it develops Aripiprazole TDS for the treatment for psychiatric disorders; Corplex Ropinirole, a transdermal patch for the treatment of Parkinson's disease; and Motion Sickness Patch, a generic transdermal product for the prevention of nausea and vomiting associated with motion sickness. Corium International, Inc. has collaboration agreements with The Procter & Gamble Company; Teva Pharmaceuticals USA, Inc.; Agile Therapeutics, Inc.; and Aequus Pharmaceuticals, Inc. The company was incorporated in 1995 and is headquartered in Menlo Park, California.
Corium International logo

Headlines

See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CORI
CUSIPN/A
Phone650-298-8255
EmployeesN/A
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$31.86 million
Book Value$0.45 per share

Profitability

Net Income$-47,790,000.00
Net Margins-155.21%

Miscellaneous

Market Cap$459.65 million
Next Earnings DateN/A
OptionableOptionable

MarketRank

Overall MarketRank

0.54 out of 5 stars

Medical Sector

1462nd out of 1,969 stocks

Pharmaceutical Preparations Industry

630th out of 771 stocks

Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Receive CORI News and Ratings via Email

Sign-up to receive the latest news and ratings for CORI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Corium International (NASDAQ:CORI) Frequently Asked Questions

What stocks does MarketBeat like better than Corium International?

Wall Street analysts have given Corium International a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Corium International wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Corium International's earnings last quarter?

Corium International, Inc. (NASDAQ:CORI) posted its earnings results on Thursday, August, 9th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, beating analysts' consensus estimates of ($0.38) by $0.04. The biopharmaceutical company had revenue of $7.67 million for the quarter, compared to the consensus estimate of $6.72 million. Corium International had a negative trailing twelve-month return on equity of 276.89% and a negative net margin of 155.21%.
View Corium International's earnings history
.

Who are Corium International's key executives?

Corium International's management team includes the following people:
  • Mr. Peter D. Staple, Pres, CEO & Director (Age 66)
  • Mr. Robert S. Breuil, Chief Financial Officer (Age 56)
  • Dr. Parminder Singh, CTO & VP of R&D (Age 54)
  • Mr. Timothy D. Sweemer CPA, Chief Accounting Officer, VP of Admin. & Sec.
  • Ms. Christina Dickerson, VP of Corp. Devel.

Who are some of Corium International's key competitors?

What other stocks do shareholders of Corium International own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corium International investors own include Intelsat (I), Iovance Biotherapeutics (IOVA), Aralez Pharmaceuticals (ARLZ), Cypress Semiconductor (CY), Energy Transfer (ET), Exelixis (EXEL), AMC Entertainment (AMC), Global Blood Therapeutics (GBT), SunCoke Energy Partners (SXCP) and Zynga (ZNGA).

What is Corium International's stock symbol?

Corium International trades on the NASDAQ under the ticker symbol "CORI."

What is Corium International's stock price today?

One share of CORI stock can currently be purchased for approximately $12.68.

How much money does Corium International make?

Corium International has a market capitalization of $459.65 million and generates $31.86 million in revenue each year. The biopharmaceutical company earns $-47,790,000.00 in net income (profit) each year or ($1.64) on an earnings per share basis.

What is Corium International's official website?

The official website for Corium International is www.coriumgroup.com.

Where are Corium International's headquarters?

Corium International is headquartered at 235 CONSTITUTION DRIVE, MENLO PARK CA, 94025.

How can I contact Corium International?

Corium International's mailing address is 235 CONSTITUTION DRIVE, MENLO PARK CA, 94025. The biopharmaceutical company can be reached via phone at 650-298-8255 or via email at [email protected]


This page was last updated on 3/7/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.